Cancer greatly impacts the health of patients and survivors and their financial conditions. After diagnosis, a person with prostate cancer is expected to pay around US$ 2,800 per month for treatment. However, depending on the insurance type and government help, these prices can be high or cheap. Costs also depend on the country and the facilities being used. Healthcare systems are increasingly embracing risk-based payment techniques in which they are responsible for their patient's healthcare costs. Healthcare systems are under pressure to provide evidence-based and efficient care in this environment. Cancer screening is an area where health systems are required to align practice with evidence-based guidelines. According to research, many individuals, notably the elderly and those with short life expectancies, are routinely screened for cancer when they are unlikely to benefit. Screening and subsequent treatment have significant downstream expenses. Hence, the high cost related to prostate cancer indirectly restrains the growth of the prostate cancer nuclear medicine diagnostics markets.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe prostate cancer nuclear medicine market. The Europe prostate cancer nuclear medicine market is expected to grow at a good CAGR during the forecast period.
Europe Prostate cancer nuclear medicine Market Segmentation
The Europe prostate cancer nuclear medicine market is segmented into type, PET product, end user, and country. Based on type, the Europe prostate cancer nuclear medicine market is divided into PET and SPECT. The PET dominated the Europe prostate cancer nuclear medicine market in 2022. Based on PET product, the Europe prostate cancer nuclear medicine market is categorized into F-18, C-11, and Ga68-PSMA. The F-18 segment dominated the Europe prostate cancer nuclear medicine market in 2022. Based on end user, the Europe prostate cancer nuclear medicine market is categorized into hospitals, clinics, and others. The hospitals segment dominated the Europe prostate cancer nuclear medicine market in 2022. Based on country, the Europe prostate cancer nuclear medicine market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The Germany segment dominated the Europe prostate cancer nuclear medicine market in 2022.
Blue Earth Diagnostics Limited; ImaginAb; Curium; Jubilant Radiopharma; ABX advanced biochemical compounds GmbH; Telix Pharmaceuticals Ltd; Novartis AG; Theragnostics; and Lantheus Medical Imaging, Inc. by Altair are among the leading companies in the Europe prostate cancer nuclear medicine market.